Related Experiment Videos
Hemoptysis: a 10-year retrospective study
J A Coss-Bu1, R C Sachdeva, J T Bricker
1Section of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030-2399, USA.
Pediatrics
|April 3, 1998
Summary
Hemoptysis is rare in children. Young adult cystic fibrosis (CF) patients with hemoptysis face higher mortality than those with congenital heart disease (CHD). Blood product transfusion predicts mortality in all patients.
Area of Science:
- Pediatric Pulmonology
- Critical Care Medicine
- Medical Outcomes Research
Background:
- Hemoptysis (coughing up blood) is infrequent in pediatric care.
- A 10-year review of hemoptysis cases in a tertiary pediatric hospital was conducted.
- The study aimed to identify patient characteristics and mortality predictors.
Purpose of the Study:
- To analyze patient demographics and clinical data for hemoptysis.
- To determine factors influencing mortality in pediatric hemoptysis cases.
- To compare outcomes between different primary diagnoses and age groups.
Main Methods:
- Retrospective review of 228 patients with 246 hemoptysis episodes over 10 years.
- Patients categorized by age (0-5, 6-10, 11-20, >20 years) and hemoptysis severity.
- Primary diagnoses included cystic fibrosis (CF), congenital heart disease (CHD), and other conditions.
Main Results:
- Overall mortality was 13%. Key predictors of mortality included age, hemoptysis amount, blood product transfusion, and fever.
- Young adult CF patients (>20 years) had higher mortality than young adult CHD patients.
- Hemoptysis amount predicted mortality solely in CHD patients, while blood product transfusion was a universal mortality predictor.
Conclusions:
- Hemoptysis commonly affects young adults with CF and adolescents with CHD.
- Young adult CF patients with hemoptysis exhibit increased mortality risk compared to young adult CHD patients.
- Blood product transfusion is a significant predictor of mortality across all studied patient groups.